ClinicalTrials.gg
CompletedNCT05794581Updated Dec 27, 2024

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

A Phase 1 interventional study of CT-868 and Placebo in Type 1 Diabetes, sponsored by Carmot Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche — none open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Hoffmann-La Roche.

Enrollment
11th of 15
32 · median 80
Started
2023
with 1 other
Phase 1
Only one
of the 15
Registered
13th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche, this one is the 11th largest by enrollment, is one of 2 that started in 2023, is the only one in phase 1, and was the 13th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche as a file.
02

Study summary

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 Diabetes
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male adults with Type 1 diabetes
  • Ages 18-65 years
  • Type 1 DM for at least 3 years
  • Using an insulin pump or multiple daily injections (MDI) for at least 3 months
  • 25.0 - 35.0

Exclusion criteria

Exclusion Criteria:

  • Significant medical history
  • Uncontrolled diabetes
  • History of surgical treatment for weight loss
  • History of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    CT-868

    SC injection of CT-868 Intervention

    Drug: CT-868

  • Placebo comparator
    Placebo

    SC injection of placebo matching CT-868 dose

    Drug: Placebo

  • Active comparator
    Victoza

    SC injection of active comparator

    Drug: Victoza

Interventions

06

What researchers measure

Primary outcomes

  1. To assess area under the curve (AUC) in glucose metabolism during MMTT

    Time frame: Baseline up to 4 days

Secondary outcomes

  1. To assess changes in continuous glucose monitoring (CGM) measures

    Time frame: Baseline up to 4 days

  2. Area under the acetaminophen concentration-time (AUC)

    Time frame: 0 - 300 minutes

07

Study locations

1 site
  • Carmot Clinical Research Unit 101
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2024, 11 months.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 11 months is above that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Apr 3, 2023
StartActual
Mar 21, 2023
Primary completionActual
Mar 6, 2024
CompletionActual
Apr 6, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05794581
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Mar 21, 2023
Primary completion
Mar 6, 2024
Completion
Apr 6, 2024
Last update
Dec 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CT-868

Start the discussion